AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05594095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPC
Description: Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
Study NCT05594095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPC
Description: Treatment of Physicians' Choice (albumin-paclitaxel, capecitabine, vinorelbine, and irbribulin)
Study NCT05476796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered intravenously on day 1 of each treatment cycle (infusion duration: 2 hours), every 2 weeks. The first cycle will be administered at level -1 (70 mg/m²) and then increased to 85 mg/m² (if feasible) from the cycle 2 to 8 or until disease progression, whatever occurs first. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and Trifluridine/Tipiracil will be continued alone until disease progression or intolerable toxicity.
Study NCT05594095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: RTK Inhibitor
Study NCT05594095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 250mg po qd
Study NCT05594095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1921
Description: TROP2 ADC
Study NCT05594095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2102
Description: NECTIN4 ADC
Study NCT05594095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A2009
Description: HER3 ADC
Study NCT05594095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1167
Description: PARP1i
Study NCT05594095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-6209
Description: CDK4i
Study NCT05594095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: bevacizumab
Study NCT04966104 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ODYSSEE-vCHAT
Description: Automated digital counselling program with social network support
Study NCT06171386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microneedling
Description: a form of collagen induction therapy
Study NCT06171386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dermabrasion
Description: a technique that improves the skin structure, quality, and appearance of scars through collagen remodeling and reepithelization
Study NCT06514807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropeginterferon alfa-2b (BESREMi®)
Description: Ropeginterferon alfa-2b 250 micrograms/0.5 mL or 500 micrograms/0.5 ml solution for injection in pre-filled pen.
Study NCT06497127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BW-00112
Description: BW-00112 or volume-matched placebo on Day 1 and Day 90
Study NCT05476796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOX regimen
Description: Folinic Acid 400 mg/m² (or 200 mg/m² if L-folinic acid) + oxaliplatin 85 mg/m² (infusion duration: 2 hours) followed by 5-FU bolus 400 mg/m² and then 5-FU 2400 mg/m² as a 46-hour continuous infusion. Treatment repeated every 14 days. In case of limiting-oxaliplatin neuropathy and in all cases after 8 cycles, oxaliplatin will be stopped and 5-FU (simplified LV5FU2 regimen) or capecitabine (1000 mg/m² BID during 2 weeks every 3 weeks) will be continued alone until disease progression or intolerable toxicity.
Study NCT05476796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years
Study NCT06278779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine group
Description: The recommended dosing for Spravato is:~Weeks 1-4:~Starting Day 1 dose:~\< 65 years: 56 mg~≥ 65 years: 28 mg~Subsequent doses:~28 mg (≥ 65 years), 56 mg or 84 mg twice weekly~Weeks 5-8:~28 mg (≥ 65 years), 56 mg or 84 mg once weekly~From Week 9:~28 mg (≥ 65 years), 56 mg or 84 mg every 2 weeks or once weekly
Study NCT06278779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Racemic ketamine
Description: Typically, dosing will begin at the standard dose of 0.5 mg/kg and adjusted as needed using an ascending dose titration schedule:~1. 0.5 mg/kg~2. 0.6 mg/kg~3. 0.75 mg/kg~4. 0.9 mg/kg~5. Further increments by 0.1-0.2 mg/kg, up to max 1.5 mg/kg
Study NCT06021496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: face to face health education
Description: Face-to-face health education with home visit
Study NCT06021496 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online health education
Description: online health education with video call
Study NCT05476796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 240 mg (infusion duration 30 minutes, every 2 weeks) until disease progression or intolerable toxicity for a maximum of 2 years
Study NCT06026488 — intervention group
Intervention type: OTHER
Intervention: Other
Description: real world treatment and survival of DLBCL patients in China
Study NCT04880174 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: serological testing
Description: Antibody testing for Sars-COV-2 antibodies in blood.
Study NCT06635629 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Desmopressin
Description: Stimulates ACTH release in Cushing disease
Study NCT06635629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desmopressin
Description: Stimulates ACTH release in Cushing disease
Study NCT06635629 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Inhibits ACTH release in Cushing disease and healthy volunteers
Study NCT05477589 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: busulfan, cyclophosphamide and melphalan, BuCyMel
Description: a three alkylator combination of busulfan, cyclophosphamide and melphalan (BuCyMel, standard arm)
Study NCT05477589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clofarabine, fludarabine and busulfan, CloFluBu
Description: combination of clofarabine, fludarabine and busulfan in which two alkylators are replaced by antimetabolites (CloFluBu, experimental arm)
Study NCT06058949 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Protection and Promotion
Description: An adaptive integrated Total Worker Health® program. Virtual 8-week program that's been contextualized to the physical and mental health needs of sign language interpreters. It will examine biomechanics, sleep hygiene, vicarious trauma and burnout, demand-control schema, physical activity, emotional management strategies, proper nutrition and examination of worksite.
Study NCT06288373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Nab paclitaxel: 260 mg/m2，D1，q3w （3 cycles），intravenous infusion, administered over 30min.
Study NCT06288373 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical surgery
Description: Radical surgery
Study NCT06058949 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Program
Description: Virtual 8-week program that addresses participant sleep hygiene, physical activity and proper nutrition.
Study NCT04772079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study NCT04772079 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching deucravacitinib
Description: Specified dose on specified days
Study NCT05591118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulant Therapy
Description: All subjects will receive anticoagulation for a minimum of 3 months.
Study NCT05591118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant Therapy
Description: All subjects will receive anticoagulation for a minimum of 3 months.
Study NCT05591118 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Catheter-Directed Therapy
Description: The endovascular physician can choose to use either mechanical thrombectomy (MT) using a device cleared by the FDA to treat PE or catheter-directed thrombolysis (CDL) using an infusion catheter cleared by the FDA to administer thrombolytic drugs for the treatment of PE
Study NCT05571449 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open reduction and internal fixation
Description: Internal fixation of the fracture
Study NCT05571449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation
Description: Internal fixation of the fracture
Study NCT05571449 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard osteosynthesis planning
Description: Plain radiograph and CT images are used
Study NCT05571449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard osteosynthesis planning
Description: Plain radiograph and CT images are used
Study NCT05571449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3-D model osteosynthesis planning
Description: A 3D plastic model made from CT images is used
Study NCT05572437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Patients randomized to the treatment with music group (classical music), after assessment of anxiety using the APAIS scale, will be given headphones and classical music will be played from their stay in the pre-anesthesia room, during surgery and in the PACU.
Study NCT06066047 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TOUCH ATTENTIVE TREATMENT
Description: 15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~Throughout the treatment, the practitioner maintained a focused attention on touch by voluntarily and constantly directing attention to the sensation/perception of the hands, perceiving texture, density, temperature, reactivity and motility of the tissue.
Study NCT06066047 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: AUDITORY ATTENTIVE TREATMENT
Description: 15-minute treatment using constant touch (0.20 N, approx. 20 grams) developed after training with visual feedback.~* 5 minutes bilateral touch on external malleolus~* 5 minutes longitudinal occipital front grip for reciprocal tension membrane movement and Sutherland's fulcrum~* 5 minutes bilateral touch on acromion, for midline, centring diaphragms~During the treatment, the operator's attention was focused on acoustic signals delivered through earphones. The beeps were delivered at random intervals between 0.5 and 2.0 seconds. The operator had to count the number of acoustic signals produced during the treatment period.
Study NCT04207437 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration therapy
Description: vibration therapy using hand held vibration device
Study NCT05080894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Embodiment of a healthy virtual body in virtual reality and action observation/motor imagery of the subject's virtual body performing high-level lower limb exercises.
Study NCT05437848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: Cotadutide
Description: Cotadutide: subcutaneous (SC) injection
Study NCT05437848 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous injection
Study NCT05027503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise with hippotherapy simulator
Description: 30-minute (5 min warm-up+20 min exercise+5 min cool-down) center-based exercise with the hippotherapy simulator will be done 2 days a week for 8 weeks.
Study NCT05027503 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Respiratory Physiotherapy
Description: Respiratory physiotherapy includes breathing control (5x2), diaphragmatic breathing exercises (5x2), thoracic expansion exercises (5x2), incentive spirometer (5x2), opep device (5x2), postural drainage and percussion and cough improvement techniques (10 min). Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks.
Study NCT05027503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Physiotherapy
Description: Respiratory physiotherapy includes breathing control (5x2), diaphragmatic breathing exercises (5x2), thoracic expansion exercises (5x2), incentive spirometer (5x2), opep device (5x2), postural drainage and percussion and cough improvement techniques (10 min). Home-based respiratory physiotherapy will be applied twice a day and every day of the week for 8 weeks.
Study NCT05474079 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise training
Description: The exercise training program will consist of individually tailored, progressive moderate-intensity aerobic exercise. Exercise training will comprise of a combination of treadmill, cross-trainer and cycle ergometer-based exercise. Exercise will progressively increase in both intensity and duration throughout the course of the intervention. Participants will begin the intervention with 30 minutes of moderate-intensity aerobic exercise at 40% HRR three times per week for the initial 4 weeks. From week 4, exercise intensity will increase to 50% HRR, and at week 6 the duration of each session will increase to 45 minutes. From week 8, participants will exercise at an intensity of 60% HRR for 45 minutes, and from week 10, this will increase to five sessions per week.
Study NCT05429814 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Menthol Application
Description: During the study, the patients' routine pharmacological treatments will continue and menthol will be applied only to reduce the effect of neuropathy. In the study, menthol 1% will be used topically, as it was used in studies after the literature review. Although it was stated in the studies that menthol had no side effects, it was decided to mix menthol with water-based cream according to the literature recommendation. Researchers will first determine how many grams of menthol will be sufficient by applying menthol to their hands and feet.After the gram of the prepared mixture is determined, it will be given to the patients. Patients in the intervention group will be taught how to regularly apply menthol cream (topical menthol) to their hands and feet, twice a day, every day. The effect on CIPN will be evaluated in patients with CIPN for 3 weeks immediately before and after 6 weeks of treatment with menthol administration.
Study NCT06312306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Anodal tDCS applied using a direct current stimulator and two saline-soaked electrodes. The anode electrodes will be positioned approximately 2 cm anterior to Cz according to the International 10/20 EEG System. The cathode will be positioned over the inion. Stimulation intensity will be at 2.0 milliampere (as suggested to achieve excitation in the lower limb motor cortex areas)
Study NCT06312306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates based core training
Description: The Pilates training program will last 30 min per session, Each action in the training will be repeated eight times these actions are at beginner level, considering the characteristics of stroke patients. The selected exercises will be given to all patients and progressed week-wise.
Study NCT06312306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy program
Description: Conventional physiotherapy program:~* Stretching Slow sustained stretching of spastic muscles (generally hip flexors and adductors, knee extensors or flexors and ankle plantar flexors)~* Strengthening Abdominals, lumbar spine extensors, hip flexors, extensors and abductors, knee extensors and flexors and ankle dorsi flexors~* Gait training In level surface and in stairs
Study NCT06312306 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy program
Description: Conventional physiotherapy program:~* Stretching Slow sustained stretching of spastic muscles (generally hip flexors and adductors, knee extensors or flexors and ankle plantar flexors)~* Strengthening Abdominals, lumbar spine extensors, hip flexors, extensors and abductors, knee extensors and flexors and ankle dorsi flexors~* Gait training In level surface and in stairs
Study NCT02384720 — intervention group
Intervention type: OTHER
Intervention: Age: 20-40years
Study NCT05469997 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean-Ketogenic Diet
Description: In the MeDi-KD group, the participants will adhere to a modified Mediterranean-ketogenic diet. The ketogenic component of the diet will require limiting the intake of carbohydrates to about 10% of all calories consumed in a day, while obtaining most of the energy from healthy fats, mostly from plant-based sources (\~70-75% of your daily caloric intake) and lean proteins (\~15-20% of your daily caloric intake). The ketogenic ratio (the ratio of fat to carbohydrates) will be gradually increased during the first week from 1:1 to 3:1. The Mediterranean component of the diet will encourage the participants to consume more green leafy vegetables, nuts, and olive oil, while limiting the consumption of processed or fried food, red meat, full-fat dairy, and sweets.
Study NCT05469997 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with medium-chain triglyceride oil
Description: The participants will adhere to the Mediterranean diet. In addition, they will be asked to take two daily doses of medium-chain triglyceride oil (MCT oil).~The MCT oil supplement (Nutiva MCT oil, Nutiva Inc.) is approved by Health Canada (NPN: 80086912) and will be used according to its approved condition of use (i.e., source of medium-chain fatty acids which supports energy production in the body at a cellular level \[ATP\]). Each serving of this product provides 130 Calories from MCTs (14 g) with a C8-C10 ratio of 60:40. Nutiva MCT oil can be mixed into any beverage of choice, but cannot be used for cooking.~participants will start the intervention by taking 5 mL of MCT oil twice daily for the first day to acclimate their bodies to the supplement and gradually increase the dose to 14 g BID by the end of week 1. The participants may be asked to increase the dose to 20 mL of MCT twice daily if tolerability remains positive.
Study NCT06288373 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: external beam radiation therapy (EBRT) + brachytherapy
Description: Radiation therapy per standard of care
Study NCT06288373 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Chemotherapy administered concurrent with radiation therapy，cisplatin 40 mg/m2 IV once per week (QW) for 5 weeks
Study NCT05016947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Tablet, taken by mouth
Study NCT05016947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Taken orally
Study NCT05016947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab Ozogamicin
Description: Intravenous infusion
Study NCT06398106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proactive TDM-based dosing of secukinumab
Description: Maintenance/normal dose is 300 mg/4 weeks.~First dose reduction step: 300 mg/6 weeks. Second dose reduction step: 300 mg/8 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 300 mg/3 weeks Second dose escalation step: 300 mg/2 weeks Further dose escalation step: shortening with 1 additional week
Study NCT06398106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proactive TDM-based dosing of ixekizumab
Description: Maintenance/normal dose is 80 mg/4 weeks.~First dose reduction step: 80 mg/6 weeks. Second dose reduction step: 80 mg/8 weeks Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 80 mg/3 weeks Second dose escalation step: 80 mg/2 weeks Further dose escalation step: shortening with 1 additional week
Study NCT06398106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proactive TDM-based dosing of guselkumab
Description: Maintenance/normal dose is 100 mg/8 weeks.~First dose reduction step: 100 mg/12 weeks. Second dose reduction step: 100 mg/16 weeks. Further dose reduction steps: prolongation with 1 additional week~First dose escalation step: 100 mg/6 weeks Second dose escalation step: 100 mg/4 weeks Further dose escalation step: shortening with 1 additional week
Study NCT05446168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tributyrin
Description: Post-biotic short chain fatty acid dietary supplement. Participants will take 500mg TID tributyrin supplement for 30 days +/- 7 days.
Study NCT06096779 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be administered at a dose of 1200 mg by IV infusion on Day 1 of each 21-day cycle.
Study NCT05235295 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided sacroiliac joint injection
Description: Using ultrasound the sacral hiatus in transverse position was identified. Then, sliding laterally and cephalad in transverse position, the posterior superior iliac spine and the posterior sacroiliac joint were identified. The needle was advanced toward the posterior joint space from medial to lateral, using an in-plane technique.
Study NCT05235295 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flouroscopy-guided sacroiliac joint injection
Description: Using anterior posterior and contralateral oblique view the posterior joint line and inferior joint margin were identified and a needle was advanced at the point the posterior inferior joint line was most clearly seen.